- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-KCAB1/ KCNAB1/ AKR6A3 monoclonal antibody
Anti-KCAB1/ KCNAB1/ AKR6A3 antibody for FACS & in-vivo assay
Go to KCNAB1/KCNAB1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP2173-Ab-1/ GM-Tg-hg-MP2173-Ab-2 | Anti-Human KCNAB1 monoclonal antibody | Human |
| GM-Tg-rg-MP2173-Ab-1/ GM-Tg-rg-MP2173-Ab-2 | Anti-Rat KCNAB1 monoclonal antibody | Rat |
| GM-Tg-mg-MP2173-Ab-1/ GM-Tg-mg-MP2173-Ab-2 | Anti-Mouse KCNAB1 monoclonal antibody | Mouse |
| GM-Tg-cynog-MP2173-Ab-1/ GM-Tg-cynog-MP2173-Ab-2 | Anti-Cynomolgus/ Rhesus macaque KCNAB1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP2173-Ab-1/ GM-Tg-felg-MP2173-Ab-2 | Anti-Feline KCNAB1 monoclonal antibody | Feline |
| GM-Tg-cang-MP2173-Ab-1/ GM-Tg-cang-MP2173-Ab-2 | Anti-Canine KCNAB1 monoclonal antibody | Canine |
| GM-Tg-bovg-MP2173-Ab-1/ GM-Tg-bovg-MP2173-Ab-2 | Anti-Bovine KCNAB1 monoclonal antibody | Bovine |
| GM-Tg-equg-MP2173-Ab-1/ GM-Tg-equg-MP2173-Ab-2 | Anti-Equine KCNAB1 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP2173-Ab-1/ GM-Tg-hg-MP2173-Ab-2; GM-Tg-rg-MP2173-Ab-1/ GM-Tg-rg-MP2173-Ab-2; GM-Tg-mg-MP2173-Ab-1/ GM-Tg-mg-MP2173-Ab-2; GM-Tg-cynog-MP2173-Ab-1/ GM-Tg-cynog-MP2173-Ab-2; GM-Tg-felg-MP2173-Ab-1/ GM-Tg-felg-MP2173-Ab-2; GM-Tg-cang-MP2173-Ab-1/ GM-Tg-cang-MP2173-Ab-2; GM-Tg-bovg-MP2173-Ab-1/ GM-Tg-bovg-MP2173-Ab-2; GM-Tg-equg-MP2173-Ab-1/ GM-Tg-equg-MP2173-Ab-2 |
| Products Name | Anti-KCNAB1 monoclonal antibody |
| Format | mab |
| Target Name | KCNAB1 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-KCNAB1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species KCAB1/ KCNAB1/ AKR6A3 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMLP003675 | human KCNAB1 Lentivirus particle |
| ORF Viral Vector | pGMLP003675 | human KCNAB1 Lentivirus plasmid |
| ORF Viral Vector | pGMLPm002620 | mouse Kcnab1 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm002620 | mouse Kcnab1 Lentivirus particle |
Target information
| Target ID | GM-MP2173 |
| Target Name | KCNAB1 |
| Gene ID | 7881,16497,29737,706635,612006,101086170,100050434 |
| Gene Symbol and Synonyms | AKR6A3,Akr8a8,hKvb3,hKvBeta3,KCNA1B,KCNAB1,KV-BETA-1,Kvb1.3,Kvbeta1.1,KvBeta3,mKv(beta)1 |
| Uniprot Accession | Q14722,P63144 |
| Uniprot Entry Name | KCAB1_HUMAN,KCAB1_RAT |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000169282 |
| Target Classification | N/A |
The target: KCNAB1, gene name: KCNAB1, also named as AKR6A3, KCNA1B, KV-BETA-1, Kvb1.3, hKvBeta3, hKvb3. Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member includes distinct isoforms which are encoded by alternatively spliced transcript variants of this gene. Some of these isoforms are beta subunits, which form heteromultimeric complexes with alpha subunits and modulate the activity of the pore-forming alpha subunits. [provided by RefSeq, Apr 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
